Becky Pferdehirt is a partner on the bio investing team. She focuses on early stage companies building technology platforms for therapeutic discovery and development.
Prior to joining Andreessen Horowitz, Becky worked at Amgen where she most recently led business development efforts for therapeutic platform partnerships. Before moving to BD Becky was a research scientist in Amgen R&D, focused on cell and gene therapy technology innovation.
Becky completed her postdoctoral education at Genentech studying cancer cell biology and proteomics. She holds a PhD in Molecular and Cellular Biology from UC Berkeley and a BS in Biology from MIT.